Chinese pharma and healthcare stocks rebound; Yangpu Medical hits 20% limit-up

The move looks like a broad-based bounce across small and mid-cap pharma names rather than a single catalyst, with the limit-up in Yangpu Medical and double-digit gains elsewhere suggesting short-term momentum chasing. It matters most for traders holding recent laggards in the sector, since the breadth of the rally — not just one stock — signals returning risk appetite. Whether this rebound holds beyond a single session, or fades as quickly as it appeared, is the open question worth watching.